BOTHELL, Wash., Dec. 13, 2017 /PRNewswire/ -- BioLife
Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer
and marketer of proprietary clinical grade biopreservation media
("BioLife" or the "Company"), today announced that it has executed
an agreement to supply its CryoStor® cell freeze media
and HypoThermosol® cell storage and shipping media to
Iovance Biotherapeutics, Inc. ("Iovance") (NASDAQ: IOVA). Iovance
is currently conducting several clinical trials for tumor
infiltrating lymphocyte (TIL) therapies targeting multiple solid
tumor types including metastatic melanoma, recurrent and/or
metastatic squamous cell carcinoma of the head and neck and
recurrent, metastatic or persistent cervical cancer.
Mike Rice, BioLife President
& CEO, commented, "We are very pleased to support the team at
Iovance in their mission to bring potentially lifesaving cancer
therapies to the market. It's very rewarding to see our proprietary
biopreservation media products being broadly adopted in the
regenerative medicine market, due to the improved yield and
extended shelf life our IP platform can offer our customers."
Commenting on the collaboration with BioLife Solutions,
Maria Fardis, PhD, MBA, President
and Chief Executive Officer of Iovance, said, "As we advance into
later stages of our clinical development, we continue building
strong collaborative relationships with our suppliers and partners.
We are pleased to have established this supply agreement with
BioLife, assuring our access to biopreservation media for storage
and shipment of our products using our Gen 2 manufacturing process,
which includes cryopreservation of our final product."
BioLife management estimates that CryoStor and HypoThermosol
have been incorporated into the manufacturing processes of at least
250 regenerative medicine applications, including numerous
late-stage clinical trials.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. is a clinical-stage
biotechnology company focused on the development of cancer
immunotherapy products for the treatment of various cancers.
Iovance's lead product candidate is an adoptive cell therapy using
tumor-infiltrating lymphocyte (TIL) technology being investigated
for the treatment of patients with metastatic melanoma, recurrent
and/or metastatic squamous cell carcinoma of the head and neck and
recurrent, metastatic or persistent cervical cancer. For more
information, please visit http://www.iovance.com.
Certain matters discussed in this press release are
"forward-looking statements" of Iovance. Iovance may, in some
cases, use terms such as "predicts," "believes," "potential,"
"continue," "estimates," "anticipates," "expects," "plans,"
"intends," "may," "could," "might," "will," "should" or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. In particular, Iovance's
statements regarding trends and potential future results are
examples of such forward-looking statements. The forward-looking
statements include risks and uncertainties, including, but not
limited to, the success, timing and cost of Iovance's ongoing
clinical trials and anticipated clinical trials for its current
product candidates, including statements regarding the timing of
initiation and completion of the trials; the timing of and its
ability to obtain and maintain U.S. Food and Drug Administration or
other regulatory authority approval of, or other action with
respect to, its product candidates; the strength of Iovance's
product pipeline; the successful implementation of Iovance's
research and development programs and collaborations; the success
of the Iovance's license or development agreements; the acceptance
by the market of Iovance's product candidates, if approved; and
other factors, including general economic conditions and regulatory
developments, not within Iovance's control. The factors discussed
herein could cause actual results and developments to be materially
different from those expressed in or implied by such
statements. A further list and description of Iovance's
risks, uncertainties and other factors can be found in Iovance's
most recent Annual Report on Form 10-K and Iovance's subsequent
filings with the Securities and Exchange Commission. Copies of
these filings are available online at www.sec.gov
or www.iovance.com. The forward-looking statements
are made only as of the date of this press release and Iovance
undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstance.
About BioLife Solutions
BioLife Solutions develops, manufactures and markets
biopreservation media products and smart shipping containers
connected to a cloud hosted cold chain management app to improve
the quality of delivery logistics for cells, tissues, and organs.
The Company's proprietary HypoThermosol® and CryoStor® platform of
solutions are highly valued in the regenerative medicine,
biobanking, and drug discovery markets. BioLife's biopreservation
media products are serum-free and protein-free, fully defined, and
are formulated to reduce preservation-induced cell damage and
death. BioLife's enabling technology provides commercial companies
and clinical researchers significant improvement in shelf life and
post-preservation viability and function of cells, tissues, and
organs. For more information please visit www.biolifesolutions.com
and follow BioLife on Twitter.
Except for historical information contained herein, this
press release contains forward-looking statements of the Company
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include, but are not
limited to, statements concerning the Company's anticipated
business and operations, the potential utility of and market for
its products and services, potential revenue growth and market
expansion, commercial manufacturing of our customers' products, and
potential customer revenue. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. These statements are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and assumptions that could cause actual results to
differ materially from those described in the forward-looking
statements, including among other things, uncertainty regarding
market adoption of products; uncertainty regarding third party
market projections; market volatility; competition; litigation; and
those other factors described in the Company's risk factors set
forth in our filings with the Securities and Exchange Commission
from time to time, including our Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q. The Company undertakes no
obligation to update the forward-looking statements contained
herein or to reflect events or circumstances occurring after the
date hereof, other than as may be required by applicable
law.
Media & Investor Relations
Roderick de Greef
Chief Financial Officer
(425) 686-6003
rdegreef@biolifesolutions.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/biolife-solutions-executes-supply-agreement-with-iovance-biotherapeutics-300570406.html
SOURCE BioLife Solutions, Inc.